ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Commercial launch of neffy^® (epinephrine nasal spray) underway in the United States
Supplemental NDA for neffy^®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025
Exclusive license agreement with ALK-Abelló to commercialize neffy^® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties
Well-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis, supporting an operating runway of at least three years
Company to host conference call and webcast today at 8:00 a.m. ET